YJYufei Jia

Yufei Jia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yufei Jia has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient delay, diagnosis delay, and treatment outcomes among migrant patients with tuberculosis in Shanghai, China, 2018-2020: a mixed-methods study

    by Yufei Jia, Weixi Jiang, Xiao Xiao, Zhexun Lou, Shenglan Tang, Jing Chen, Qian Long

    Objectives This study aimed to examine patient delay, diagnosis delay and treatment performance among patients with tuberculosis (TB) in Shanghai, China in 2018–2020 focusing on disparities between migrant and local patients with TB. Design Mixed-method study. Setting and participants Quantitative data were collected from the TB information management system in Shanghai; 17 533 bacteriologically confirmed and clinically diagnosed patients with pulmonary TB registered in 2018–2020 were included. Qualitative interviews were conducted with TB administrators (n=3) and community healthcare providers (two groups, n=10 in total) from Shanghai. Main outcome measures Patient delay, diagnosis delay and treatment completion were examined by resident type using descriptive analysis and logistic regressions. Qualitative interviews were conducted to understand factors associated with the disparities. Results From 2018 to 2020, migrant patients with TB accounted for 44.40% of total cases. There was no significant difference in patient delay between migrant and local patients (18.47 days on average). 22.12% of migrants and 16.52% of locals experienced diagnosis delays exceeding 14 days, respectively. After adjusting for all variables, migrant patients (OR 1.30, 95% CI 1.18 to 1.44) and initial care seeking at general hospitals (OR 3.76, 95% CI 3.45 to 4.09) were associated with a higher probability of diagnosis delay. 93.9% of migrant patients and 89.4% of the local patients had a successful TB treatment without statistically significant difference after adjusting for all variables. Qualitative interviews revealed a standard approach to managing patients with TB in Shanghai no matter their resident type. Young migrant patients who were able to maintain their jobs in Shanghai often had better treatment adherence. Despite patients’ COVID-19 fear and limited care access in 2020, TB treatment minimally affected for both due to community-based case management. Conclusions Migrant patients were more likely to experience diagnosis delay. It should improve awareness and knowledge of TB among healthcare professionals at general hospitals to mitigate the risk of diagnosis delay.


  • Open Access

    Trastuzumab Accessibility and Utilization for Breast Cancer Treatment in an eastern prefecture-level city in China: Does health insurance coverage matter?

    by Xingxia Yang, Yufei Jia, Jianhong Xu, Qin Zhou, Qian Long, Yi Yang, Yunguo Liu, Juanying Zhu, Xiaochen Zhang

    Background Trastuzumab, a monoclonal antibody for breast cancer, faces global accessibility challenges, especially in low- and middle-income countries, primarily due to high costs. This study examines the impact of medical insurance policy changes and price reductions on Trastuzumab utilization in China, using JX city as a case study, to provide insights into improving drug accessibility and affordability. Methods This retrospective study investigated Trastuzumab utilization among HER2-positive breast cancer patients at a tertiary hospital from May 2013 to December 2022 in JX, a prefecture-level city located in eastern China. Patients were stratified based on their CerbB2 indicator. Patients with a 2 + CerbB2 status require further FISH testing to confirm HER2 expression for Trastuzumab eligibility, while patients with a 3 + CerbB2 status directly qualifies for the treatment. We analyzed the utilization rates of FISH test and Trastuzumab using logistic regressions, identifying factors that influence their usage. Results 766 patients were included in this study. The utilization rate of Trastuzumab among patients with CerbB2 3 + rose from 40.40–77.94% in September 2017 following the expansion of insurance coverage, and further increased to 90.41% after a price reduction in 2020. The FISH test was not covered by health insurance, and it was not available in the local hospital until Trastuzumab became available in JX city. For patients with CerbB2 2+, the proportion undergoing the FISH test increased dramatically from 8.89–82.08% after the price reduction in 2020. The mere inclusion into basic medical insurance, regardless of insurance types, significantly increased the utilization of Trastuzumab and the FISH test. However, rural patients in JX city are still facing financial burdens with Trastuzumab's out-of-pocket cost accounting for 62.9% of their annual disposable income in 2020. Conclusions Our findings indicate that expanding insurance coverage and reducing the price significantly increased Trastuzumab utilization. Additionally, improving the accessibility of the FISH test plays a crucial role in enhancing the uptake of Trastuzumab among eligible patients. These insights are essential for informing policies in China and other low- and middle-income countries towards achieving universal health coverage.

  • Open Access

    Cost Drivers and Financial Burden for Cancer-Affected Families in China: A Systematic Review

    by Yufei Jia, Weixi Jiang, Bolu Yang, Shenglan Tang, Qian Long

    This systematic review examined cancer care costs, the financial burden for patients, and their economic coping strategies in mainland China. We included 38 quantitative studies that reported out-of-pocket payment for cancer care and patients’ coping strategies in English or Chinese (PROSPERO: CRD42021273989). We searched PubMed, Embase, Ovid, Web of Science, Cochrane, CNKI, and Wanfang Data from 1 January 2009 to 10 August 2022. We referred to the standards for reporting observational studies to assess the methodological quality and transparent reporting of the included studies and reported the costs narratively. Annual mean medical costs (including inpatient and outpatient costs and fees for self-purchasing drugs) ranged from USD 7421 to USD 10,297 per patient. One study investigated medical costs for 5 years and indicated that inpatient costs accounted for 51.6% of the total medical costs, followed by self-purchasing drugs (43.9%). Annual medical costs as a percentage of annual household income ranged from 36.0% to 63.1% with a metaproportion of 51.0%. The common coping strategies included borrowing money and reduction of household expenses and expenses from basic health services. Costs of inpatient care and self-purchasing drugs are major drivers of medical costs for cancer care, and many affected households shoulder a very heavy financial burden.